Asset profile
dostarlimab-gxly · GSK (GSK)
- Indication
- MSI-H/dMMR locally advanced rectal cancer
- Also known as
- Jemperli
Company
GSKGSK
GSKGSKIn the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology,…
On the calendar
Nothing scheduled in this window.
Timeline
Newest first.
Registered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT06278857 | Phase 2 | Recruiting | Jun 30, 2026 | 10 | 0 of 3 sites in the United States |
More from GSK
Other drugs and candidates from the same company tracked in this sector.
bepirovirsenchronic hepatitis B (CHB) in adults without cirrhosis on NrtI therapy ≥6 months with suppressed HBV DNA and HBsAg ≤3000 IU/mlboron-based LeuRS inhibitorstuberculosisShingrixshingles preventiontebipenem HBrcomplicated urinary tract infections (cUTIs) including pyelonephritisVENTANA MMR RxDx PaneldMMR and pMMR solid tumors (colorectal, endometrial, gastric, small intestine, biliary)